The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma

Table 3 Multivariate analyses of prognostic factors based on Cox regression model

Outcomes	Variables in the final model	HR (95% CI)	P*
OS	Interval (> 30 vs. ≤ 30 days)	2.44 (1.48–4.01)	< 0.001
	N category (N2–3 vs. N0–1)	2.13 (1.44–3.16)	< 0.001
	CCI (≥ 1 vs. 0)	2.21 (1.38–3.54)	0.001
	Age (continuous)	1.02 (1.00–1.04)	0.042
	lnDNA (continuous)	1.04 (0.98–1.10)	0.173
	T category (T3–4 vs. T1–2)	1.42 (0.85–2.36)	0.183
DFS	Interval (> 30 vs. ≤ 30 days)	1.99 (1.27–3.11)	0.003
	CCI (≥ 1 vs. 0)	1.87 (1.26–2.79)	0.002
	N category (N2–3 vs. N0–1)	1.58 (1.14–2.18)	0.006
	lnDNA (continuous)	1.06 (1.01–1.10)	0.018
	Age (continuous)	1.01 (1.00–1.03)	0.126
DMFS	Interval (> 30 vs. ≤ 30 days)	2.62 (1.54–4.47)	< 0.001
	N category (N2–3 vs. N0–1)	3.03 (1.93–4.77)	< 0.001
	lnDNA (continuous)	1.12 (1.04–1.20)	0.002
	CCI (≥ 1 vs. 0)	1.50 (0.84–2.66)	0.171
LRFS	Interval (> 30 vs. ≤ 30 days)	1.53 (0.76–3.08)	0.238
	WHO pathology (III vs. I/II)	0.42 (0.20–0.89)	0.023
	N category (N2–3 vs. N0–1)	0.63 (0.37–1.07)	0.086
	lnDNA (continuous)	1.06 (0.99–1.13)	0.099

Covariates including: age (continuous), gender (female vs. male), CCI score (≥ 1 vs. 0), T category (T3–4 vs. T1–2), N category (N2–3 vs. N0–1), lnDNA (continuous), WHO pathology type (III vs. I/II), IC cycles (> 2 vs. ≤ 2), concurrent chemotherapy (yes vs. no)
Abbreviations: OS Overall survival, DFS Disease-free survival, DMFS Distant metastasis-free survival, LRFS Locoregional recurrence-free survival, IC Induction chemotherapy, CCI Charlson comorbidity index, HR Hazard ratio, CI Confidence interval
*Wald chi-square test

ISSN: 1748-717X